Bakkt reported $80.8 million of Q2 2026 net income attributable to the company, but the profit was driven primarily by a dramatic increase in the carrying value of its investment in Transchem Limited. Bakkt had paid approximately $9.4 million toward the Transchem warrant subscription, while the 47.5 million warrants were valued at $107.9 million at June 30.
The accounting effect was substantial. Bakkt recognized a $98.5 million non-cash gain from the change in fair value of the Transchem warrants during the quarter, along with a $1.4 million non-cash gain from a legacy warrant liability. Those gains helped move the company from a $14.7 million net loss in Q2 2025 to an $80.8 million profit, equivalent to $1.96 per basic share and $1.94 per diluted share.
The underlying operating picture was markedly different. Bakkt’s adjusted EBITDA loss widened to $11.8 million from $9.8 million, a $2 million deterioration. The company attributed the change primarily to lower crypto-services revenue net of associated costs, higher salary and contract-labor expense and a loss from an equity-method investment, partially offset by lower SG&A.
The contrast illustrates the unusually large effect that the Transchem investment currently has on Bakkt’s reported results. Changes in the warrant position are recorded at fair value through earnings each period, meaning subsequent movements in Transchem’s valuation could continue to create significant gains or losses that are separate from Bakkt’s operating performance.
Bakkt received the warrants after obtaining the required Indian regulatory approvals. The $9.4 million already paid represented 25% of the aggregate subscription amount, while approximately $28.2 million remained payable upon full exercise at June 30. Bakkt may exercise the warrants in one or more tranches within 18 months of issuance.
The Transchem position forms the largest component of Bakkt’s broader strategic asset portfolio. Bakkt reported Strategic Asset Value of approximately $118.6 million, consisting of the $107.9 million Transchem warrant position and a $10.6 million carrying value for its equity-method investment in Bitcoin Japan.
Bakkt’s liquidity at quarter-end was considerably smaller than the carrying value of those strategic assets. Cash, cash equivalents and restricted cash totaled $50.7 million, up from $27.5 million at year-end, while the company had no long-term debt. First-half liquidity included $48.1 million of gross proceeds from a registered direct offering and $21.5 million from sales under its at-the-market program.
Q2 revenue was $170.1 million compared with $568.1 million a year earlier, a 70% decline reflecting client transitions and weaker digital-asset trading volumes. However, most reported crypto revenue is offset by corresponding crypto costs and execution, clearing and brokerage fees, which totaled $169.3 million during the quarter.
Operationally, Bakkt processed $168.8 million of Total Transacting Volume in Q2 and $410 million during the first half. Management continues to target approximately $2.5 billion of TTV for the full year, assuming integrations and partner activations ramp substantially during the second half.
Bakkt is also preparing additional products for commercialization. Bakkt Agent Embedded Finance is available for partner integration, while initial co-branded card programs, a conversational financial interface and Neobank-as-a-Service offerings are targeted for Q4 2026, subject to partner, banking, network and regulatory requirements.
KEY QUOTES:
“Bakkt is building a financial operating system for the AI and token economy through three complementary engines: Bakkt Markets, our regulated infrastructure layer; Bakkt Agent, our intelligence layer; and Bakkt Global, our opportunity layer. During the quarter, we made tangible progress across all three.”
“Bakkt Global also reached an important milestone. Following the receipt of the required regulatory approvals in India, Transchem allotted 47.5 million warrants to Bakkt. As of June 30, 2026, the warrant position had a reported fair value of $107.9 million, compared with approximately $9.4 million paid to date. But the strategic opportunity extends well beyond the value recognized today. Bitcoin Japan provides a foothold in Japan’s private-capital and innovation ecosystem, while Transchem supports our broker-led distribution strategy in India. Over time, Bakkt’s Markets and Agent stack can connect eligible global and private-market assets with scaled local distribution, subject to required approvals and product readiness.”
Akshay Naheta, Chief Executive Officer of Bakkt
